Publication

Video

Supplements and Featured Publications

Therapeutic Changes in HER2+ Breast Cancer
Volume1
Issue 1

Novel Treatments in HER2-Positive Breast Cancer

OncLive interviewed experts on novel treatments in HER2-positive breast cancer. 

OncLive interviewed experts on novel treatments in HER2-positive breast cancer.

Supported by an unrestricted educational grant by Daiichi Sankyo

Articles in this issue
Novel Treatments in HER2-Positive Breast Cancer
Novel Treatments in HER2-Positive Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
1 expert in this video
1 expert in this video
Related Content
peterschreiber.media– stock.adobe.com
November 22nd 2024

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

Susana M. Campos, MD, MPH
November 21st 2024

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Francisco J. Esteva, MD, PhD, of Northwell Health
November 22nd 2024

Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer

D. Ross Camidge, MD, PhD; Rahul Gosain, MD, MBA, medical director, Wilmot Cancer Institute at Webster, director, Wilmot Cancer Institute Regional Infusion services, assistant professor, clinical medicine, Department of Medicine, Hematology/Oncology, University of Rochester
November 20th 2024

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs | Image Credit: © Katsyarina - stock.adobe.com
November 22nd 2024

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs

RP1 Plus Nivolumab in Advanced Melanoma
November 22nd 2024

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma